267 related articles for article (PubMed ID: 26197856)
1. Platinum sensitivity and non-cross-resistance of cisplatin analogue with cisplatin in recurrent cervical cancer.
Takekuma M; Kuji S; Tanaka A; Takahashi N; Abe M; Hirashima Y
J Gynecol Oncol; 2015 Jul; 26(3):185-92. PubMed ID: 26197856
[TBL] [Abstract][Full Text] [Related]
2. Second platinum therapy in patients with uterine cervical cancer previously treated with platinum chemotherapy.
Tanioka M; Katsumata N; Yonemori K; Kouno T; Shimizu C; Tamura K; Ando M; Fujiwara Y
Cancer Chemother Pharmacol; 2011 Aug; 68(2):337-42. PubMed ID: 20976599
[TBL] [Abstract][Full Text] [Related]
3. Applicability of the concept of "platinum sensitivity" to recurrent endometrial cancer: the SGSG-012/GOTIC-004/Intergroup study.
Nagao S; Nishio S; Michimae H; Tanabe H; Okada S; Otsuki T; Tanioka M; Fujiwara K; Suzuki M; Kigawa J
Gynecol Oncol; 2013 Dec; 131(3):567-73. PubMed ID: 24076450
[TBL] [Abstract][Full Text] [Related]
4. Platinum-based combination chemotherapy vs. weekly cisplatin during adjuvant CCRT in early cervical cancer with pelvic LN metastasis.
Lee YY; Park W; Huh SJ; Yoon A; Park JY; Choi CH; Kim TJ; Lee JW; Kim BG; Bae DS
Anticancer Res; 2013 Oct; 33(10):4675-81. PubMed ID: 24123048
[TBL] [Abstract][Full Text] [Related]
5. Platinum-free interval in second-line chemotherapy for recurrent cervical cancer.
Matoda M; Tanigawa T; Omatsu K; Ushioda N; Yamamoto A; Okamoto S; Kawamata Y; Kato K; Umayahara K; Takeshima N
Int J Gynecol Cancer; 2013 Nov; 23(9):1670-4. PubMed ID: 24172102
[TBL] [Abstract][Full Text] [Related]
6. [Comparison of two different chemotherapy regimens for concurrent chemoradiotherapy in stage Ib2 to IVa squamous cell carcinoma of the uterine cervix].
Li XF; Li YH; Gao YN; Li CL; Yue HZ; Xu G; Li DM; Su X
Zhonghua Fu Chan Ke Za Zhi; 2013 Oct; 48(10):763-7. PubMed ID: 24406134
[TBL] [Abstract][Full Text] [Related]
7. The concept of platinum sensitivity could be applied to recurrent cervical cancer: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group.
Takekuma M; Mori K; Iida T; Kurihara K; Saitou M; Tokunaga H; Kawana K; Ikeda M; Satoh T; Saito T; Miyagi E; Nagai Y; Furusawa A; Kawano Y; Kawano K; Tabata T; Ota Y; Hayase R; Mikami M; Sugiyama T
Cancer Chemother Pharmacol; 2017 Oct; 80(4):697-705. PubMed ID: 28785994
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors from a randomized phase III trial of paclitaxel and carboplatin versus paclitaxel and cisplatin in metastatic or recurrent cervical cancer: Japan Clinical Oncology Group (JCOG) trial: JCOG0505-S1.
Nishio S; Kitagawa R; Shibata T; Yoshikawa H; Konishi I; Ushijima K; Kamura T
Cancer Chemother Pharmacol; 2016 Oct; 78(4):785-90. PubMed ID: 27553435
[TBL] [Abstract][Full Text] [Related]
9. What is an appropriate second-line regimen for recurrent endometrial cancer? Ancillary analysis of the SGSG012/GOTIC004/Intergroup study.
Nagao S; Nishio S; Okada S; Otsuki T; Fujiwara K; Tanabe H; Takano M; Hasumi Y; Takei Y; Hasegawa T; Matsumoto T; Fujiwara K; Takekuma M; Nakamura K; Shimada M; Suzuki M; Kigawa J
Cancer Chemother Pharmacol; 2015 Aug; 76(2):335-42. PubMed ID: 26092322
[TBL] [Abstract][Full Text] [Related]
10. Cervical non-squamous carcinoma: an effective combination chemotherapy of taxane, anthracycline and platinum for advanced or recurrent cases.
Kimura T; Miyatake T; Ueda Y; Ohta Y; Enomoto T; Kimura T; Kamiura S
Eur J Obstet Gynecol Reprod Biol; 2012 Oct; 164(2):200-4. PubMed ID: 22770633
[TBL] [Abstract][Full Text] [Related]
11. Response to Combination Chemotherapy With Paclitaxel/Ifosfamide/Platinum Versus Paclitaxel/Platinum for Patients With Metastatic, Recurrent, or Persistent Carcinoma of the Uterine Cervix: A Retrospective Analysis.
Choi HJ; Paik ES; Choi CH; Kim TJ; Lee YY; Lee JW; Bae DS; Kim BG
Int J Gynecol Cancer; 2018 Sep; 28(7):1333-1341. PubMed ID: 30045137
[TBL] [Abstract][Full Text] [Related]
12. Feasibility and Safety of Negative-Balance Isolated Pelvic Perfusion in Patients with Pretreated Recurrent or Persistent Uterine Cervical Cancer.
Murata S; Onozawa S; Sugihara F; Sakamoto A; Ueda T; Yamaguchi H; Yasui D; Mine T; Kumita S
Ann Surg Oncol; 2015 Nov; 22(12):3981-9. PubMed ID: 25758191
[TBL] [Abstract][Full Text] [Related]
13. The outcome of advanced or recurrent non-squamous carcinoma of the uterine cervix after platinum-based combination chemotherapy.
Kastritis E; Bamias A; Efstathiou E; Gika D; Bozas G; Zorzou P; Sarris K; Papadimitriou C; Dimopoulos MA
Gynecol Oncol; 2005 Nov; 99(2):376-82. PubMed ID: 16051322
[TBL] [Abstract][Full Text] [Related]
14. The activity of carboplatin and paclitaxel for recurrent cervical cancer after definitive radiotherapy.
Mabuchi S; Morishige K; Fujita M; Tsutsui T; Sakata M; Enomoto T; Kimura T
Gynecol Oncol; 2009 May; 113(2):200-4. PubMed ID: 19268342
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505.
Kitagawa R; Katsumata N; Shibata T; Kamura T; Kasamatsu T; Nakanishi T; Nishimura S; Ushijima K; Takano M; Satoh T; Yoshikawa H
J Clin Oncol; 2015 Jul; 33(19):2129-35. PubMed ID: 25732161
[TBL] [Abstract][Full Text] [Related]
16. A retrospective analysis of cisplatin/carboplatin plus paclitaxel in advanced or recurrent cervical cancer.
Song D; Kong W; Zhang T; Han C; Liu T; Jiao S; Chen J
J Obstet Gynaecol; 2019 Apr; 39(3):389-394. PubMed ID: 30663464
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of carboplatin and cisplatin in advanced or recurrent squamous carcinoma of the uterine cervix.
Morris M; Gershenson DM; Burke TW; Mitchell MF; Levenback C; Atkinson N; Wharton JT
Gynecol Oncol; 1994 May; 53(2):234-8. PubMed ID: 8188085
[TBL] [Abstract][Full Text] [Related]
18. The toxicity and long-term efficacy of nedaplatin and paclitaxel treatment as neoadjuvant chemotherapy for locally advanced cervical cancer.
Yin M; Zhang H; Li H; Li X; Liu Y; Chen X; Lou G; Li K
J Surg Oncol; 2012 Feb; 105(2):206-11. PubMed ID: 21815150
[TBL] [Abstract][Full Text] [Related]
19. [Analysis of prognostic factors and therapeutic patterns of recurrent stage Ⅰb-Ⅱa cervical squamous carcinoma treated with radical hysterectomy].
Ou ZJ; Zhao D; An JS; Sun CY; Huang MN; Li B; Wu LY
Zhonghua Fu Chan Ke Za Zhi; 2019 Jun; 54(6):399-405. PubMed ID: 31262124
[No Abstract] [Full Text] [Related]
20. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
